NCT01255475

Blood Pressure Reduction in Heart Failure

Effect of Blood Pressure Reduction in Patients With Chronic Heart Failure - Randomized, Double-blind, Placebo-controlled Trial

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 21 (actual)
• Sponsor: University of Sao Paulo · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Previous studies have demonstrated a direct association between blood pressure level and cardiovascular risk. However in patients with heart failure this association is considered controversial. The aim of this study is to evaluate the effect of the reduction of blood pressure in patients with heart failure. The investigators will examine the effects of this intervention over mortality, quality of life, and cardiac function.

Conditions

• Heart Failure
• Cardiac Failure
• Congestive Heart Failure

Interventions

Type	Name	Description
DRUG	Hydralazine/amlodipine	Patients will receive drug therapy aimed to reducing blood pressure - first line drug will be hydralazine up to 100mg/day; if systolic blood pressure reduces less than 20% from baseline and remains over 100mmHg patients will further receive amlodipine up to 10mg/day
DRUG	Placebo	Patients will receive placebo

Timeline

• Start date: 2011-01-01
• Primary completion: 2012-10-01
• Completion: 2013-01-01
• First posted: 2010-12-07
• Last updated: 2014-06-10

Locations

1 site across 1 country: Brazil